The Belgian Competition Authority imposes a fine of €2.7M for abuse of dominance on a pharmaceutical company (Novartis)
The Belgian Competition Authority imposes a fine of EUR 2 782 808 on Novartis for abuse of dominant position*
The Competition College of the Belgian Competition Authority has
L'accès à cet article est réservé aux abonnés
Déjà abonné ? Identifiez-vous